Study guide
6.1 Ethical Foundations and the 2024 Declaration of Helsinki
ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Format, Eligibility and Registration
1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions
2 Chapter 2: CRA Responsibilities and Study Planning
2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy
3 Chapter 3: Protocols, Endpoints and Trial Design
3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs
4 Chapter 4: Bias Control, Blinding and Product Information
4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates
5 Chapter 5: Estimands and Device Instructions
5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training
6 Chapter 6: Ethical Foundations and Independent Oversight
6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review
7 Chapter 7: Ethics Communication and Informed Consent
7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates
8 Chapter 8: Recruitment, Retention and Confidentiality
8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access
9 Chapter 9: Safety Definitions and Classification
9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information
10 Chapter 10: Safety Detection, Reporting and Oversight
10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight
11 Chapter 11: Follow-Up, Adherence and Conflicts
11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments
12 Chapter 12: Development Stages and Product Management
12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response
13 Chapter 13: Accountability, Integrity and Regulatory Status
13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting
14 Chapter 14: Current GCP Principles and Delegation
14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority
15 Chapter 15: Oversight, Protocol Control and Amendments
15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution
16 Chapter 16: Implementation and Trial Responsibilities
16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles
17 Chapter 17: Quality Planning, Root Causes and CAPA
17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification
18 Chapter 18: Risk Assessment and Monitoring Methods
18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review
19 Chapter 19: Quality Metrics, Plans and Communication
19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication
20 Chapter 20: Site Qualification and Readiness
20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release
21 Chapter 21: Initiation, Equipment and Supplies
21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies
22 Chapter 22: Samples, Diagnostics and Financial Feasibility
22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility
23 Chapter 23: Interim Monitoring and Reporting
23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports
24 Chapter 24: Essential Records, Audits and Findings
24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning
25 Chapter 25: Close-Out, Retention and Destruction
25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access
26 Chapter 26: Source Records and Good Documentation
26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context
27 Chapter 27: Electronic Systems, Metadata and Queries
27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning
28 Chapter 28: Dataset Finalisation and Critical Data
28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings
6.1 Ethical Foundations and the 2024 Declaration of Helsinki
Key Takeaways Explain This Topic AI
Participant rights, safety and well-being take priority over scientific or commercial aims.
The current Declaration of Helsinki includes the October 2024 revision.
Respect for persons, beneficence and justice help explain consent, risk assessment and fair selection.
Last updated: October 2026
Ethical Foundations and the 2024 Declaration of Helsinki
Note
Clinical research ethics is not merely a set of administrative rules; it represents a hard-won framework of moral principles developed in direct response to historical atrocities and human exploitation in biomedical experimentation. Every CRA must understand the origins of these standards to recognize ethical breaches during site monitoring.
Clinical trials rely on the willingness of human volunteers to accept potential risks and inconveniences to generate generalizable medical knowledge. Because clinical research inevitably introduces risks that offer no guaranteed personal therapeutic benefit, the global biomedical community operates under strict ethical codes designed to safeguard human rights, safety, dignity, and autonomy.
For the Clinical Research Associate (CRA), ethical oversight is a continuous operational responsibility. Monitors verify that investigative sites honor the voluntary nature of participation, protect vulnerable individuals from undue influence, and ensure that trial burdens and benefits are equitably distributed.
The Evolution of Research Ethics Frameworks
Modern Good Clinical Practice (GCP) guidelines—most notably ICH E6—synthesize principles articulated across three foundational historical documents: the Nuremberg Code, the Declaration of Helsinki, and the Belmont Report.
Historical context
The Nuremberg Code emphasised voluntary participation and avoidance of unjustified harm. The Belmont Report's respect for persons, beneficence and justice provide useful ethical vocabulary for autonomy, risk-benefit evaluation and fair selection. The ECO mentions Belmont in a task example; ACRP's current reference list specifically includes ICH guidelines and the Declaration of Helsinki. Study the current references and apply the principles to monitoring, rather than memorising long historical quotations.
The Declaration of Helsinki (World Medical Association)
Adopted in 1964 by the World Medical Association (WMA) in Helsinki, Finland, and subsequently updated across multiple assemblies including the October 2024 revision, the Declaration of Helsinki sets ethical principles for all people, teams and organisations involved in medical research.
While the Nuremberg Code emerged from criminal jurisprudence, the Declaration of Helsinki adapted these concepts into clinical medical practice. Key ethical tenets include:
Primacy of the Individual: The health, well-being, and rights of the individual research participant must always take precedence over the interests of science and society. Pure scientific interest can never justify exposing participants to disproportionate harm.
Physician's Primary Duty: The physician's fundamental duty is to promote and safeguard the health, well-being, and rights of patients, including those involved in medical research.
Independent Ethical Review: Mandates that every clinical trial protocol must be submitted for consideration, comment, guidance, and approval to an independent research ethics committee before the study begins.
Restrictions on Placebo Controls: A new intervention must be tested against the best proven existing intervention (standard of care). The use of placebo, or no intervention, is acceptable only in studies where no proven intervention exists, or where for compelling and scientifically sound methodological reasons the use of placebo is necessary to determine efficacy or safety and the participants who receive placebo will not be subject to any risk of serious or irreversible harm.
Publication and Transparency: Researchers, authors, sponsors, and editors have ethical obligations regarding the publication of research findings. Negative and inconclusive results must be published or otherwise made publicly available alongside positive findings.
Post-Trial Access: In advance of a clinical trial, sponsors and investigators must make provisions for post-trial access to interventions identified as beneficial in the trial for participants who still need them, with any exceptions considered through the ethics-reviewed arrangements described in the current Declaration.
The Belmont Report (1979)
In the United States, public outrage surrounding the revelation of the Tuskegee Syphilis Study (1932–1972)—in which impoverished African American men were deliberately denied effective penicillin treatment for decades to study the natural progression of untreated syphilis—led Congress to pass the National Research Act of 1974.
This legislation created the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, which issued The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research in 1979.
The Belmont Report identifies three foundational ethical principles and operationalizes them into specific regulatory applications:
Belmont Principle Core Philosophical Mandate Operational Application in Clinical Research
Respect for Persons Acknowledges personal autonomy and guarantees protection for individuals with diminished autonomy. Informed Consent: Demands that participants be given comprehensive information, evaluate it with complete comprehension, and volunteer freely without coercion or undue influence.
Beneficence Enforces the moral obligation to secure participant well-being through two rules: (1) do no harm, and (2) maximize possible benefits while minimizing potential harms. Risk-Benefit Assessment: Requires investigators, sponsors, and IRBs to conduct a rigorous, systematic evaluation of research risks against anticipated direct and societal benefits.
Justice Demands fairness in the distribution of research burdens and benefits; forbids exploiting vulnerable groups for the benefit of privileged populations. Equitable Subject Selection: Forbids selecting subjects based on social stigmatization, institutionalization, or convenience; requires fair inclusion and exclusion criteria.
Official sources
Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , WMA Declaration of Helsinki, 2024 , ICH E11(R1) .